Activating transcription factor 2 mediates matrix metalloproteinase-2 transcriptional activation induced by p38 in breast epithelial cells

Cancer Research

Volumn 66, Issue 21, 2006, Pages 10487-10496

  Song, Hyun ^a   Ki, Sung Hwan ^b   Kim, Sang Geon ^b   Moon, Aree ^a  

^a Duksung Women's University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACTIVATING TRANSCRIPTION FACTOR 2; GELATINASE A; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BINDING SITE; BREAST EPITHELIUM; CELL INVASION; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; DOSE RESPONSE; DRUG INHIBITION; ENZYME ACTIVITY; EPITHELIUM CELL; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE H RAS; PHENOTYPE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; UPREGULATION;

ACTIVATING TRANSCRIPTION FACTOR 2; BINDING SITES; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL CELLS; FEMALE; GENES, RAS; HUMANS; MAP KINASE KINASE 6; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1;

EID: 33751270700     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1461     Document Type: Article

References (49)

1. Stetler-Stevenson WG. Type-IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1999;9:289-303.
2. Tryggvason K. Type-IV collagenase in invasive tumors. Breast Cancer Res Treat 1993;24:209-18.
3. Ura H, Bonfil RD, Reich R, et al. Expression of type IV collagenases and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human bronchial epithelial cells. Cancer Res 1989;49:4615-21.
4. Johnsen M, Lund LR, Romer J, Almholt K, Dano K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 1998;10:667-71.
5. Moon A, Kim MS, Kim TG, et al. H-ras, but not N-ras, induces an invasive phenotype in human breast epithelial cells: a role for MMP-2 in the H-ras-induced invasive phenotype. Int J Cancer 2000;85:176-81.
6. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003;89:1270-5.
7. Talvensaar-Mattila A, Paako P, Blanco-Sequeiro G, et al. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 2001;65:55-61.
8. Qin H, Sun Y, Benveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999;274:29130-7.
9. Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1997;17:6330-8.
10. Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS, Lovett DH. A functional activating protein 1 (AP-I) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J 2003;369:485-96.
11. Clair T, Miller WR, Cho-Chung YS. Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer. Cancer Res 1987;47:5290-3.
12. Clark GJ, Der CJ. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 1995;35:133-44.
13. Moon A. Differential functions of Ras for malignant phenotypic conversion. Arch Pharm Res 2006;29:113-22.
14. Kim MS, Lee EJ, Kim HR, Moon A. p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res 2003;63:5454-61.
15. Shin I, Kim S, Song H, Kim HR, Moon A. H-Ras-specific activation of Rac-MKK3/6-p38 pathway: its critical role in invasion and migration of breast epithelial cells. J Biol Chem 2005;280:14675-83.
16. Raingeaud J, Gupta S, Rogers JS, et al. Proinflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995;270:7420-6.
17. Ahn S, Olive M, Aggarwal S, Krylov D, Ginty DD, Vinson C. A dominant-negative inhibitor of CREB reveals that it is a general mediator of stimulus-dependent transcription of c-fos. Mol Cell Biol 1998;18:967-77.
18. Steinmuller L, Cibelli G, Moll JR, et al. Regulation and composition of activator protein 1 (AP-1) transcription factors controlling collagenase and c-Jun promoter activities. Biochem J 2001;360:599-607.
19. Kim ES, Kim MS, Moon A. Transforming growth factor (TGF)-β in conjunction with H-ras activation promotes malignant progression of MCF10A breast epithelial cells. Cytokine 2005;29:84-91.
20. Ma Z, Qin H, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-γ and IFN-β: critical role of STAT-1α. J Immunol 2001;167:5150-9.
21. Ki SH, Cho IJ, Choi DW, Kim SG. Glucocorticoid receptor (GR)-associated SMRT binding to C/EBPβ TAD and Nrf2 Neh4/5: role of SMRT recruited to GR in GSTA2 gene repression. Mol Cell Biol 2005;25:4150-65.
22. Sabeh F, Ota I, Holmbeck K, et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MTI-MMP. J Cell Biol 2004;167:769-81.
23. Zhu T, Lobie PE. Janus kinase 2-dependent activation of p38 mitogen-activated protein kinase by growth hormone. Resultant transcriptional activation of ATF-2 and CHOP, cytoskeletal re-organization, and mitogenesis. J Biol Chem 2000;275:2103-14.
24. Waas WF, Lo HH, Dalby KN. The kinetic mechanism of the dual phosphorylation of the ATF2 transcription factor by p38 mitogen-activated protein (MAP) kinase α. Implications for signal/response profiles of MAP kinase pathways. J Biol Chem 2001;276:5676-84.
25. Emonard H, Marcq V, Mirand C, Hornebeck W. Inhibition of gelatinase A by oleic acid. Ann N Y Acad Sci 1999;30:647-9.
26. Bodey B, Bodey B, Jr., Groger AM, Siegel SE, Kaiser HE. Invasion and metastasis: the expression and significance of matrix metalloproteinases in carcinomas of the lung. In vivo 2001;15:175-80.
27. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996;7:147-54.
28. Sato H, Kida Y, Mai M, et al. Expression of genes encoding type IV collagen-degrading metalloproteinase and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 1992;7:77-83.
29. Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003;36:128-37.
30. Kita D, Takino T, Nakada M, Takahashi T, Yamashita J, Sato H. Expression of dominant-negative form of Ets-1 suppresses fibronectin-stimulated cell adhesion and migration through down-regulation of integrin α5 expression in U251 glioma cell line. Cancer Res 2001;61:7985-91.
31. Behrens P, Rothe M, Florin A, Wellmann A, Wernert N. Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1, and MMP-9 expression. Int J Mol Med 2001;8:149-54.
32. Hahne JC, Okuducu AF, Kaminski A, Florin A, Soncin F, Wernert N. Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion, and anchorage-independent growth. Oncogene 2005;24:5384-8.
33. Li JJ, Westergaard C, Ghosh P, Colburn NH. Inhibitors of both nuclear factor-κB and activator protein-1 activation block the neoplastic transformation response. Cancer Res 1997;57:3569-76.
34. Li JJ, Rhim JS, Schlegel R, Vousden KH, Colburn NH. Expression of dominant negative Jun inhibits elevated AP-1 and NF-κB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene 1998;16:2711-21.
35. Li JJ, Cao Y, Young MR, Colburn NH. Induced expression of dominant-negative c-jun downregulates NFκB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes. Mol Carcinog 2000;29:159-69.
36. Ludes-Meyers JH, Liu Y, Munoz-Medellin D, Hilsenbeck SG, Brown PH. AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene 2001;20:2771-80.
37. Sato H, Kita M, Seiki M. v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J Biol Chem 1993;268:23460-8.
38. Sato H, Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993;8:395-405.
39. Brown PD, Levy AT, Margulies IM, Liotta LA, Stetler-Stevenson WG. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 1990;50:6184-91.
40. Tryggvason K, Huhtala P, Tuuttila A. Chow L, Keski-Oja J, Lohi J. Structure and expression of type IV collagenase genes. Cell Differ Dev 1990;32:307-12.
41. Bachmeier BE, Albini A, Vene R, et al. Cell density-dependent regulation of matrix metalloproteinase and TIMP expression in differently tumorigenic breast cancer cell lines. Exp Cell Res 2005;305:83-98.
42. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4:E131-6.
43. Bakiri L, Matsuo K, Wisniewska M, Wagner EF, Yaniv M. Promoter specificity and biological activity of tethered AP-1 dimers. Mol Cell Biol 2002;22:4952-64.
44. Matsuyama W, Kamohara H, Galligan C, Faure M, Yoshimura T. Interaction of discoidin domain receptor 1 isoform b (DDR1b) with collagen activates p38 mitogen-activated protein kinase and promotes differentiation of macrophages. FASEB J 2003;17:1286-8.
45. Nyormoi O, Bar-Eli M. Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis 2003;20:251-63.
46. Gupta S, Campbell D, Derijard B, Davis RJ. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995;267:389-93.
47. van Dam H, Wilhelm D, Herr I, Steffen A, Herrlich P, Angel P. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J 1995;14:1798-811.
48. Ouwens DM, de Ruiter ND, van der Zon GC, et al. Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RaIGDS-Src-p38. EMBO J 2002;21:3782-93.
49. Sevilla A, Santos CR, Vega FM, Lazo PA. Human vaccinia-related kinase 1 (VRK1) activates the ATF2 transcriptional activity by novel phosphorylation on Thr-73 and Ser-62 and cooperates with JNK. J Biol Chem 2004;279:27458-65.